Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Viking Therapeutics (VKTX) over the last 4 years, with Dec 2024 value amounting to -$1.01.

  • Viking Therapeutics' EPS (Weighted Average and Diluted) fell 268.18% to -$0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.12, marking a year-over-year decrease of 127.96%. This contributed to the annual value of -$1.01 for FY2024, which is 10.99% down from last year.
  • Per Viking Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$1.01 for FY2024, which was down 10.99% from -$0.91 recorded in FY2023.
  • Over the past 5 years, Viking Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.71 during FY2021, and registered a low of -$1.01 during FY2024.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$0.94, with a median of -$0.91 in 2023.
  • Data for Viking Therapeutics' EPS (Weighted Average and Diluted) shows a maximum YoY dropped of 26.76% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Viking Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.71 in 2021, then fell by 26.76% to -$0.90 in 2022, then declined by 1.11% to -$0.91 in 2023, then dropped by 10.99% to -$1.01 in 2024.